Furthermore, the majority of the data from the studies correlating the incidence of Notch mutations and clinical outcomes of T-ALL indicate that activating mutations of the Notch1 gene or inactivating mutations of the Fbxw7 gene, which encodes a ubiquitin ligase instrumental for Notch degradation, are associated with a favorable prognosis to conventional therapies [33]–[36]. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.